2004
DOI: 10.1016/j.transproceed.2004.04.097
|View full text |Cite
|
Sign up to set email alerts
|

Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4

Citation Types

3
36
0

Year Published

2008
2008
2014
2014

Publication Types

Select...
7
1

Relationship

0
8

Authors

Journals

citations
Cited by 40 publications
(39 citation statements)
references
References 18 publications
3
36
0
Order By: Relevance
“…16) As the present patients with anemia were managed by blood transfusions to maintain their level of Hct at >20%, it may be necessary to take Hct fluctuations into consideration when assessing C/D ratios. 17) Hct levels were stable at 26.7± 6.6% and 25.7± 4.0% during pre-to post-engraftment, respectively, and we had a good correlation between concentrations and clinical conditions. In addition, concentrations were assessed as C/D ratios and were compared between pre-and post-stages as variation ratios.…”
Section: Discussionsupporting
confidence: 51%
“…16) As the present patients with anemia were managed by blood transfusions to maintain their level of Hct at >20%, it may be necessary to take Hct fluctuations into consideration when assessing C/D ratios. 17) Hct levels were stable at 26.7± 6.6% and 25.7± 4.0% during pre-to post-engraftment, respectively, and we had a good correlation between concentrations and clinical conditions. In addition, concentrations were assessed as C/D ratios and were compared between pre-and post-stages as variation ratios.…”
Section: Discussionsupporting
confidence: 51%
“…As is the case with other rapamycin analogs, ridaforolimus exhibits saturable binding to erythrocytes and subsequently a relatively high blood to plasma ratio [10][11][12]. This characteristic inXuences selection of matrix for evaluation (i.e., plasma versus blood).…”
Section: Discussionmentioning
confidence: 99%
“…Although the DFC formulation differs from the formulation proposed for marketing (i.e., ECT), the DFC formulation was administered both when ridaforolimus was given alone and in combination with ketoconazole to avoid a potential confounding effect of formulation. As with other rapamycin analogs, ridaforolimus exhibits saturable binding to erythrocytes that results in a relatively high blood to plasma ratio [3,14,15]. Given the relatively low ridaforolimus levels in plasma, the pharmacokinetic results in this evaluation are based on wholeblood, not plasma, exposures.…”
Section: Discussionmentioning
confidence: 99%